title: A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.
abstract: BACKGROUND
  Standard therapy for lymphoma consists of a cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P) (CHOP) combination regimen. Liposomal daunorubicin (DaunoXome) is an alternative to doxorubicin for patients with lymphoma because of its more favorable safety profile and potentially more selective uptake in lymphoma. The objectives of this study were to determine the maximum tolerated dose (MTD) of liposomal daunorubucin with CVP (COP-X) and the tolerability of the regimen in patients with indolent lymphoma.
  
  
  METHODS
  Patients with low-grade and intermediate-grade lymphoma having adequate cardiac, hepatic, and renal function were enrolled. Patients received C 750 mg/m2, V 1.4 mg/m2 (maximum 2.0 mg), and liposomal daunorubicin 50-100 mg/m2 i.v. on day 1 and P 100 mg p.o. on days 1-5. MTD was the liposomal daunorubicin dose associated with 20% dose-limiting toxicity (ANC < 500/mm3 for > 5 days or febrile neutropenia).
  
  
  RESULTS
  Twenty patients, median age 59 years, were treated. The liposomal daunorubicin MTD combined with CVP was 70-80 mg/m2, depending on patient population. No significant non-hematologic toxicity occurred. Response rate was 44% (2 complete and 5 partial responses).
  
  
  CONCLUSIONS
  A liposomal daunorubicin dose of 80 mg/m2 in the COP-X regimen was well tolerated with little nonhematologic toxicity.
authors.affiliation: The Johns Hopkins University, Baltimore, Maryland, USA. iflinn@jhmi.edu
authors.forename: I W
authors.initials: IW
authors.lastname: Flinn
authors.forename: S N
authors.initials: SN
authors.lastname: Goodman
authors.forename: L
authors.initials: L
authors.lastname: Post
authors.forename: J
authors.initials: J
authors.lastname: Jamison
authors.forename: C B
authors.initials: CB
authors.lastname: Miller
authors.forename: S
authors.initials: S
authors.lastname: Gore
authors.forename: L
authors.initials: L
authors.lastname: Diehl
authors.forename: C
authors.initials: C
authors.lastname: Willis
authors.forename: R F
authors.initials: RF
authors.lastname: Ambinder
authors.forename: J C
authors.initials: JC
authors.lastname: Byr
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008081:Liposomes; D008099:Liver / Q000187:drug effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D008081:Liposomes; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone; D003630:Daunorubicin